Kornimate/medical-research-clean huggingface dataset:
comparative efficiency of three regimen, cefci, cef and ec as neoadjuvant chemotherapy for primary breast cancer

Conditions: Breast Cancer

Summary: this is a phase iv, prospective, single-center, open-label, randomized, controlled study. eligible patients are randomly assigned into three groups. the investigators propose to evaluate and compare the efficacy and safety of different neoadjuvant chemotherapies in women with primary breast cancer.


Eligibility criteria:
inclusion criteria: * female patients, age ≦ 65 years old * histologically or cytologically confirmed primary breast cancer by core biopsy * disease stage appropriate for neoadjuvant chemotherapy (t2～t3，n0～2，m0) * no previous treatment for breast cancer * no history of other malignancies * no currently uncontrolled diseased (e.g., ongoing cardiac dysrhythmias, unstable diabetes) or active infection * no history of other malignancies * no currently uncontrolled diseased or active infection * not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential * adequate cardiovascular function reserve without a myocardial infarction within the past six month * adequate hematologic function with: 1. absolute neutrophil count (anc) ≥ 1500/mm3 2. platelets ≥ 100,000/ mm3 3. hemoglobin ≥ 10 g/dl * adequate hepatic and renal function with: 1. serum bilirubin ≤ 1.5×unl 2. alkaline phosphatase and alanine aminotransferase (alt) ≤ 2.5 x uln. 3. serum creatinine ≤ 1.7 mg/dl * knowledge of the investigational nature of the study and ability to give informed consent * ability and willingness to comply with study procedures exclusion criteria: * known or suspected distant metastases * concurrent malignancy or history of other malignancy * uncontrolled diseases or active infection * hepatic or renal dysfunction as detailed above * geographical, social, or psychological problems that would compromise study compliance * known or suspected hypersensitivity to cyclophosphamide, epirubicin and fluorouracil

Keywords: primary breast cancer
a trial comparing the uncovered to the covered wallstent in the palliation of malignant bile duct strictures

Conditions: Inoperable Tumors of the Bile Duct

Summary: the purpose of the study is to determine the best management of bile duct narrowing (stricture) due to inoperable tumors. the bile duct is a tube that carries bile formed in the liver to the small bowel to digest fats. tumors around the bile duct can compress the duct causing pain, jaundice (yellow skin and eyes), itchy skin and fever.

this is a prospective randomized trial conducted at 4 large teaching hospitals (brigham and women's hospital, massachusetts general hospital, and boston medical center, boston, massachusetts, and mayo clinic, rochester, minnesota). malignancy is determined by pathology. cancer stage is determined by transabdominal imaging and/or endoscopic ultrasound (eus). written informed consent is obtained from each of the enrolled patients. the study is approved by the institutional review boards at each of the participating centers.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age. * malignant bile duct stricture. * increased bilirubin. * duct stricture is ≥ 1 cm distal to the biliary hilum (bifurcation of the common hepatic duct into the right and left hepatic ducts). * not an operative candidate. exclusion criteria: * unable to obtain consent. * unable to tolerate procedure. * suspected benign bile duct stricture. * candidate for potentially curative surgical intervention. * previous metallic biliary stent. * previous bile duct surgery.
preoperative ultrasound-guided peri- capsular nerve group block on postoperative analgesia after shoulder arthroscopic surgery

Conditions: Preoperative; Ultrasound-Guided; PeriCapsular Nerve Group Block; Postoperative Analgesia; Shoulder Arthroscopic Surgery

Summary: this study aimed to evaluate the analgesic efficacy of preoperative ultrasound-guided peri-capsular nerve group block (peng) on postoperative analgesia after shoulder arthroscopic surgery.

postoperative pain control after shoulder surgery is challenging, and poor pain management is invariably reflected in poor outcomes, with longer hospitalization and recovery time. the difﬁculty in reducing pain due to the complexity of shoulder innervation leads to conducting studies to explore selective axillary nerve blocks with a posterior approach or from the axillae. the peri-capsular nerve group (peng) block is a regional anesthetic technique. it can be effectively and safely applied under ultrasound guidance in shoulder surgery cases for postoperative analgesia. it targets only the sensory branches and not the posterior mechanoreceptors; there is a potential motor-sparing effect which is desirable for better physical therapy, and earlier discharge.

Eligibility criteria:
inclusion criteria: * age from 21 to 65 years. * both sexes. * american society of anesthesiologists (asa) physical status i-iii. * scheduled for unilateral shoulder arthroscopic surgery. exclusion criteria: * patient refusal. * known hypersensitivity to local anesthetics. * body mass index\> 35 kg /m2. * uncooperative or psychiatric patients. * infection at the injection site. * coagulation disorder. * major cardiac, renal, or hepatic diseases.
spine school for parents with disabled children

Conditions: Spine Deformity

Summary: our first aim in this study is to investigate the effects of neck exercise and information training given to parents of disabled children with non-specific neck pain on parameters such as pain, disability level, quality of life, posture, physical activity, and spinal curvature.


Eligibility criteria:
inclusion criteria: * volunteer parents between the ages of 18-65, with spinal problems and chronic pain, pain lasting longer than 3 months, no inflammatory pain, no pain originating from abdominal-pelvic organs will be included in the study. exclusion criteria: * individuals with acute fractures and malignancies, cervical disc herniation, those who have undergone surgical operations in the cervical region or spine, those with upper extremity pathologies, and those with rheumatological, neurological and psychological disorders will be excluded from the study.

Keywords: disabled children parents spine health
association between body mass index and hfnc therapy success

Conditions: Covid19; Obesity; Overweight; Pneumonia, Viral

Summary: patients over 18 years of age who are admitted to the intermediate care unit of the clinica del country and the clinica la colina, with symptoms suggestive of severe pneumonia secondary to covid-19 infection and acute hypoxemic respiratory failure. the primary outcome will be to determine the relationship between body mass index and high-flow cannula therapy success defined as: no need for mechanical ventilation.

all adult patients over 18 years of age admitted to the intermediate care service of the participating center with suspected sars-cov-2 pneumonia will be considered as potential candidates for the study. the medical records of patients in our cohort who require high-flow cannula therapy and who met all the inclusion criteria and none of the exclusion criteria will be reviewed.all data will be processed and analyzed using the spss 26 software once the study is completed. study sample

Eligibility criteria:
inclusion criteria: 1. patients over 18 years of age. 2. diagnosis of severe pneumonia secondary to covid-19 infection and acute respiratory distress syndrome, defined by upper and lower respiratory symptoms plus positive c-reactive protein test for covid-19. 3. patient admission to the clinical del country and clinica de la colina intermediate care units. 4. oxygen therapy by high-flow system (high-flow cannula) requirement. 5. anthropometric data availability upon admission to our facilities. exclusion criteria: 1. patients with a survival expectancy of less than 12 months according to the charlson scale categorization or patients with oncological pathology. 2. patients under 18 years of age. 3. pregnant women. 4. patients with cardiogenic pulmonary edema. 5. history of chronic liver disease or cirrhosis child - pugh c. 6. patients with contraindications to high-flow cannula therapy initiation. 7. patients with respiratory, hemodynamic and neurological indications that contraindicate hfnc initiation.
comparison of co2 laser versus co2 laser with prp in scars

Conditions: CO2 Laser in Scars

Summary: objective: to compare the effect of fractional carbon dioxide laser (fcl) vs fractional carbon dioxide laser with platelet rich plasma (prp) in management of scars. study design: randomized-controlled trial (rct). study setting and duration: dermatology department, cmh-abbottabad, november 2022/april 2023. methodology: the sample size of 60 patients, age 18 to 50 years, was calculated by using openepi app and the non-probability consecutive sampling technique was used. patient in group a received fcl treatment's four sessions with four weeks apart, whereas group b received four prp and fcl sessions. the quartile grading scale (score 0 is \ 75% improvement) was used to assess the patient's clinical improvement at 4 weeks after each session. to determine statistical significance χ2-square test, taking p-value \<0.05 as significant, was used.


Eligibility criteria:
inclusion criteria: * patients aged 18-50 years * fitzpatrick skin type iii-v * presented with post-acne, post traumatic or post burn scars * all those patients emotionally balanced with realistic expectations were included in the study. exclusion criteria: * scar that was less than 6 months old * if they had an active infection or inflammatory skin condition * having a history of malignancy * a known connective tissue illness * history of excessive bleeding or keloids * unrealistic expectations * pregnant or breastfeeding.
impact of an oral health intervention

Conditions: Eating Disorder

Summary: this pilot study will assess the effectiveness of an original oral health education program on affecting the behaviors of patients diagnosed with eating disorders.


Eligibility criteria:
inclusion criteria: * patient of the unc center for excellence for eating disorders inpatient unit or outpatient clinic. * diagnosis of anorexia nervosa or bulimia nervosa * aged 13-50 years * english-speaking exclusion criteria: * decisionally impaired (i.e., incapable of providing informed consent in the opinion of the primary care provider in unc center for excellence for eating disorders) * involuntarily committed to the inpatient service of the unc department of psychiatry

Keywords: anorexia nervosa bulimia
relationship between renal function and pharmacokinetics of apixaban and clinical outcome of apixaban in thai non-valvular atrial fibrillation patients

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to assess pharmacokinetics and pharmacodynamics of apixaban and clinical outcome of apixaban in thai patients with nonvalvular atrial fibrillation with varying degree of creatinine clearance

this study is divided into two parts. the first part is a multiple dose pharmacokinetic and pharmacodynamics study of apixaban in patient with stable renal function. the primary purpose of this study is to provide a clear understanding of the effect of creatinine clearance on pharmacokinetics and pharmacodynamics of apixaban among thai patients with nonvalvular atrial fibrillation. to assess the pharmacokinetics and pharmacodynamics of apixaban, this study will enroll 30 subjects who meet the inclusion criteria. the second part of this study will retrospectively determine the occurrent of clinical outcome between patients who were prescribed apixaban dose concordant and discordant to the drug leaflet. a total of 241 subjects will be recruited. the follow up period will begin from the time of initiation of apixaban until occurrent of stoke, transient ischemic attack, systemic embolism, bleeding, or death.

Eligibility criteria:
part i inclusion criteria: * patients with nonvalvular atrial fibrillation * patients who is receiving a stable dose of apixaban for primary or secondary prevention of stroke, transient ischemic attack, and systemic embolism. exclusion criteria: * pregnant or lactating * end stage renal disease patients who required chronic renal replacement therapy to sustained life * history of acute kidney injury within the previous 3 months * severe hepatic impairment (child-pugh class c) * any gastrointestinal disorder that could impact the absorption of study drug * cyp3a4 moderate/strong inhibitors: ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, naproxen, clarithromycin, rifampicin, phenytoin, carbamazepine, phenobarbital, diltiazem, and st.john's wort part ii inclusion criteria: * patients with nonvalvular atrial fibrillation * patients who was prescribed apixaban for primary or secondary prevention of stroke, transient ischemic attack, and systemic embolism. exclusion criteria: * pregnant or lactating

Keywords: apixaban pharmacokinetic pharmacodynamic cardioembolic stroke ischemic stroke
safety and efficacy of the dali ldl-adsorber and monet lipoprotein filter

Conditions: Hypercholesterolemia, Familial; LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA

Summary: low density lipoprotein (ldl)-apheresis refers to a procedure in which blood taken from a patient's vein is cleaned from pathogenic substances, e.g. cholesterol, outside the body and then given back to the patient. in the dali (direct adsorption of lipoproteins)-system whole blood is pumped over an adsorber containing beads that selectively bind ldl-cholesterol. the monet (membrane filtration optimized novel extracorporeal treatment)-system works with plasma which is cleaned by filtration. this study comprises the recording of safety and efficacy data from patients treated either with the dali or monet-system over a period of 2 years.

data were recorded from patients suffering from familial hypercholesterolemia and treated by lipid apheresis using one of the two systems investigated for at least 3 months prior to inclusion in the study. only those treatments were documented in which routine blood samples for laboratory analysis were taken, or in which adverse or serious adverse device effects occur.

Eligibility criteria:
inclusion criteria: * given informed consent * 18 years or older * patient compliant to therapy as prescribed * at least two therapy sessions per month * treatment with dali or monet system for at least 3 months before inclusion * last severe invasive intervention in hospital more than 3 months ago exclusion criteria: * earlier participation in the study * unconscious patient/persons without capacity to contract * for dali: intake of ace-inhibitors

Keywords: dali adsorber monet lipoprotein filter
efficacy of triple-daily 15ma tacs on adolescent nssi

Conditions: Self-Injurious Behavior

Summary: in order to assess the clinical efficacy of triple-daily 15ma-tacs stimulation by comparing the effects of active and sham tacs interventions on driving improvements in adolescent nonsuicidal self-injury(nssi), participants will be randomly assigned to either the active or sham tacs group. this trial consists of a 2-week intensified intervention phase (40 sessions), followed by a 4-week observation period. the key hypothesis is that triple-daily 15ma-tacs stimulation will enhance clinical recovery compared to sham stimulation.

recognizing the clinical shortcomings of traditional methods for adolescent nssi, study objective is to establish evidence supporting the efficacy of a triple-daily 15ma-tacs stimulation regimen targeting the forehead and both mastoids. this intervention will be administered five days a week over a four-week treatment period, with the aim of eliciting substantial clinical improvements in adolescent nssi compared to a sham intervention. on the first day of the intervention, participants will receive a tacs session, followed by triple-daily tacs sessions administered for 13 consecutive days. following the completion of treatment, participants will undergo follow-up observations every 7 days for 4 weeks. eeg and ecg recordings will be obtained at baseline, on day 1 after the first session, at the end of the 2-week intervention period (after 40 sessions), and at the 6-week follow-up. throughout the sessions, all evaluations will be conducted under standardized conditions.

Eligibility criteria:
inclusion criteria: * diagnosis of nssi based on the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) criteria section 3 diagnostic criteria. * five or more nssi episodes in the past year and at least one nssi episode in the past month. * age between 12 and 21 years. * informed consent from parents or legal guardians. * informed consent from participants aged 15 years and above. exclusion criteria: * current or history of organic brain disorders or neurological disorders. * elevated or imminent suicidal risk, as assessed by clinicians during routine screening. * previous or current exposure to electroconvulsive therapy (ect), modified ect, tms, transcranial direct current stimulation (tdcs), tacs, or other neurostimulation treatments. * presence of cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain. * previous or current use of psychotropic medication. * pregnancy or lactation. * participation in another concurrent clinical trial. * refusal to provide informed consent to participate in the trial. * other circumstances deemed unsuitable for participation by researchers.

Keywords: transcranial alternating current stimulation (tacs) non-invasive brain stimulation
mindfulness based cognitive therapy for psychological distress in pregnancy

Conditions: Depression; Anxiety; Stress

Summary: anxiety, stress and depression are common during pregnancy and in the postpartum period. the lack of empirically supported, non-pharmaceutical interventions for psychological distress in pregnancy is a significant gap in the literature, especially given many pregnant women's preference for non-pharmaceutical treatments. this study will evaluate the efficacy of mindfulness based cognitive therapy (mbct) program in reducing measures of psychological distress (e.g., symptoms of stress, depression and anxiety) in a group of pregnant women endorsing high levels of distress.


Eligibility criteria:
inclusion criteria: eligible women for this study * are between 12 and 28 weeks of gestation, * are experiencing psychological distress (elevated perinatal anxiety, mild depressive symptoms, or high-levels of self-reported stress) exclusion criteria: * current suicidality * current substance abuse or dependence * experience a current major depressive episode * have been diagnosed with bipolar disorder or other disorders that have a psychotic, dissociative, hallucinatory, or delusional component * taking prescribed medications that affect sleep or mood

Keywords: pregnancy postpartum mindfulness based cognitive therapy depression anxiety stress mbct actigraphy
vibration in boys with a history of fracture

Conditions: Fracture

Summary: boys aged 9-12 years, with a history of facture will be asked to stand on one of two vibrating platforms for 10 minutes on 5 consecutive days. the investigators will take blood samples before and after the vibration to measure changes in the bone cells.

fractures in children are common, accounting for 10% of attendances in accident and emergency departments. research into risk factors for fracture has found that children who have narrower bones and a low bone mass are more likely to fracture than children with larger bones. studies in postmenopausal women, young women with low bone mass and children with disabling conditions such as cerebral palsy, have shown that up to 10 minutes a day stood on a vibrating platform can significantly increase bone mass. however little is known of the immediate response of bone to whole body vibration (wbv). the investigators previously investigated the acute bone response in healthy pre-pubertal boys to standing on one of two vibrating platforms for 10 minutes on 1, 3 or 5 consecutive days. this showed a platform dependent reduction in the bone resorption marker ctx pre to post vibration, with an increase in the bone formation marker p1np over the 8 day study. the investigators would like to look at the response of bone to wbv in pre-pubertal boys who have a history of fracture(s). the investigators will compare this to the investigator's previous data to determine if bone in boys who have previously fractured responds in the same way as bone in boys who have not. the investigators plan to recruit 24 boys aged 9-12 years who have had a previous fracture to stand on one of two vibrating platforms for 10 minutes on 5 consecutive days. before and after the period of vibration on days 1, 3, 5, and on days 8 and 12 the investigators will take a blood sample to measure changes in the bone cells. the boys will be asked about the amount of exercise they have participated in over the previous seven days. the findings of this study will be used to direct further research.

Eligibility criteria:
inclusion criteria: * caucasian * aged 7-13yrs (pre-pubertal) * first language english * history of one or more fracture(s) exclusion criteria: * pre-existing chronic illness * known bone disease * current or healing fracture * recent (last 12 months) or current treatment likely to affect bone - this does not include inhaled or intermittent oral therapy with steroids for asthma * balance problems * continuing involvement in more than one other research study
study of the safety and efficacy of two fixed doses of opc-34712 as adjunctive therapy in the treatment of adults with major depressive disorder (the polaris trial)

Conditions: Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders

Summary: to compare the effect of opc-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned fda approved antidepressant treatment (adt) in patients with major depressive disorder who demonstrate an incomplete response to a prospective trial of the same assigned fda approved adt


Eligibility criteria:
inclusion criteria: * male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by dsm-iv-tr criteria * the current depressive episode must be equal to or greater than 8 weeks in duration * subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments exclusion criteria: * females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug * subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration * subjects with a current axis i (dsm-iv-tr) diagnosis of: delirium, dementia, amnestic or other cognitive disorder, schizophrenia, schizoaffective disorder, or other psychotic disorder, bipolar i or ii disorder * subjects with a clinically significant current axis ii (dsm-iv-tr) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder

Keywords: opc-34712 brexpiprazole major depressive disorder adjunctive treatment